|
1
|
Curado MP and Hashibe M: Recent changes in
the epidemiology of head and neck cancer. Curr Opin Oncol.
21:194–200. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Molinolo AA, Amornphimoltham P, Squarize
CH, et al: Dysregulated molecular networks in head and neck
carcinogenesis. Oral Oncol. 45:324–334. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choi S and Myers JN: Molecular
pathogenesis of oral squamous cell carcinoma: implications for
therapy. J Dent Res. 87:14–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bromberg J and Darnell JE Jr: The role of
STATs in transcriptional control and their impact on cellular
function. Oncogene. 19:2468–2473. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rane SG and Reddy EP: Janus kinases:
components of multiple signaling pathways. Oncogene. 19:5662–5679.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Aggarwal BB, Kunnumakkara AB, Harikumar
KB, et al: Signal transducer and activator of transcription-3,
inflammation, and cancer: how intimate is the relationship? Ann NY
Acad Sci. 1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Reich NC and Liu L: Tracking STAT nuclear
traffic. Nat Rev Immunol. 6:602–612. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chung J, Uchida E, Grammer TC and Blenis
J: STAT3 serine phosphorylation by ERK-dependent and -independent
pathways negatively modulates its tyrosine phosphorylation. Mol
Cell Biol. 17:6508–6516. 1997.PubMed/NCBI
|
|
9
|
Decker T and Kovarik P: Serine
phosphorylation of STATs. Oncogene. 19:2628–2637. 2000. View Article : Google Scholar
|
|
10
|
Venkatasubbarao K, Choudary A and Freeman
JW: Farnesyl transferase inhibitor (R115777)-induced inhibition of
STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines
require extracellular signal-regulated kinases. Cancer Res.
65:2861–2871. 2005. View Article : Google Scholar
|
|
11
|
Lim CP and Cao X: Serine phosphorylation
and negative regulation of STAT3 by JNK. J Biol Chem.
274:31055–31061. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
O’Shea JJ, Gadina M and Schreiber RD:
Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.
Cell. 109:S121–S131. 2002.PubMed/NCBI
|
|
13
|
Bromberg J: Stat proteins and oncogenesis.
J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Song JI and Grandis JR: STAT signaling in
head and neck cancer. Oncogene. 19:2489–2495. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grandis JR, Drenning SD, Zeng Q, et al:
Constitutive activation of Stat3 signaling abrogates apoptosis in
squamous cell carcinogenesis in vivo. Proc Natl Acad Sci USA.
97:4227–4232. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nikitakis NG, Siavash H and Sauk JJ:
Targeting the STAT pathway in head and neck cancer: recent advances
and future prospects. Curr Cancer Drug Targets. 4:637–651. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kijima T, Niwa H, Steinman RA, et al:
STAT3 activation abrogates growth factor dependence and contributes
to head and neck squamous cell carcinoma tumor growth in vivo. Cell
Growth Differ. 13:355–362. 2002.PubMed/NCBI
|
|
18
|
Leeman RJ, Lui VW and Grandis JR: STAT3 as
a therapeutic target in head and neck cancer. Expert Opin Biol
Ther. 6:231–241. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Siavash H, Nikitakis NG and Sauk JJ:
Abrogation of IL-6-mediated JAK signalling by the cyclopentenone
prostaglandin 15d-PGJ(2) in oral squamous carcinoma cells. Br J
Cancer. 91:1074–1080. 2004.PubMed/NCBI
|
|
20
|
Lee TL, Yeh J, Van Waes C and Chen Z:
Epigenetic modification of SOCS-1 differentially regulates STAT3
activation in response to interleukin-6 receptor and epidermal
growth factor receptor signaling through JAK and/or MEK in head and
neck squamous cell carcinomas. Mol Cancer Ther. 5:8–19. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Naher L, Kiyoshima T, Kobayashi I, et al:
STAT3 signal transduction through interleukin-22 in oral squamous
cell carcinoma. Int J Oncol. 41:1577–1586. 2012.PubMed/NCBI
|
|
22
|
Jewett A, Head C and Cacalano NA: Emerging
mechanisms of immunosuppression in oral cancers. J Dent Res.
85:1061–1073. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lai SY and Johnson FM: Defining the role
of the JAK-STAT pathway in head and neck and thoracic malignancies:
implications for future therapeutic approaches. Drug Resist Updat.
13:67–78. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maggioni D, Gaini R, Nicolini G, et al:
MAPKs activation in head and neck squamous cell carcinomas. Oncol
Rev. 5:223–231. 2011. View Article : Google Scholar
|
|
25
|
Johnson GL and Lapadat R:
Mitogen-activated protein kinase pathways mediated by ERK, JNK, and
p38 protein kinases. Science. 298:1911–1912. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pearce AK and Humphrey TC: Integrating
stress-response and cell-cycle checkpoint pathways. Trends Cell
Biol. 11:426–433. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dunn C, Wiltshire C, MacLaren A and
Gillespie DA: Molecular mechanism and biological functions of c-Jun
N-terminal kinase signalling via the c-Jun transcription factor.
Cell Signal. 14:585–593. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jain N, Zhang T, Fong SL, et al:
Repression of Stat3 activity by activation of mitogen-activated
protein kinase (MAPK). Oncogene. 17:3157–3167. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sengupta TK, Talbot ES, Scherle PA and
Ivashkiv LB: Rapid inhibition of interleukin-6 signaling and Stat3
activation mediated by mitogen-activated protein kinases. Proc Natl
Acad Sci USA. 95:11107–11112. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Quadros MR, Peruzzi F, Kari C and Rodeck
U: Complex regulation of signal transducers and activators of
transcription 3 activation in normal and malignant keratinocytes.
Cancer Res. 64:3934–3939. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kovarik P, Stoiber D, Eyers PA, et al:
Stress-induced phosphorylation of STAT1 at Ser727 requires p38
mitogen-activated protein kinase whereas IFN-gamma uses a different
signaling pathway. Proc Natl Acad Sci USA. 96:13956–13961. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ahmed ST, Mayer A, Ji JD and Ivashkiv LB:
Inhibition of IL-6 signaling by a p38-dependent pathway occurs in
the absence of new protein synthesis. J Leukoc Biol. 72:154–162.
2002.PubMed/NCBI
|
|
33
|
Tkach M, Rosemblit C, Rivas MA, et al:
p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for
progestin-induced full activation of Stat3 and breast cancer
growth. Endocr Relat Cancer. 20:197–212. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen RJ, Ho YS, Guo HR and Wang YJ: Rapid
activation of Stat3 and ERK1/2 by nicotine modulates cell
proliferation in human bladder cancer cells. Toxicol Sci.
104:283–293. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gough D, Koetz L and Levy D: The MEK-ERK
pathway is necessary for serine phosphorylation of mitochondrial
STAT3 and Ras-mediated transformation. PLoS One. 8:e833952013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xue P, Zhao Y, Liu Y, Yuan Q, et al: A
novel compound RY10-4 induces apoptosis and inhibits invasion via
inhibiting STAT3 through ERK-, p38-dependent pathways in human lung
adenocarcinoma A549 cells. Chem Biol Interact. 209:25–34. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee MH, Huang Z, Kim DJ, et al: Direct
targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest
and inhibits melanoma cell growth. Cancer Prev Res. 6:455–465.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Aguzzi A, Maggioni D, Nicolini G, et al:
MAP kinase modulation in squamous cell carcinoma of the oral
cavity. Anticancer Res. 29:303–308. 2009.PubMed/NCBI
|
|
39
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Z, Gibson TB, Robinson F, et al: MAP
kinases. Chem Rev. 101:2449–2476. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lee SH, Lee JW, Soung YH, et al:
Colorectal tumors frequently express phosphorylated
mitogen-activated protein kinase. APMIS. 112:233–238. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Mendoza MC, Er EE and Blenis J: The
Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends
Biochem Sci. 36:320–328. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Anjum R and Blenis J: The RSK family of
kinases: emerging roles in cellular signalling. Nat Rev Mol Cell
Biol. 9:747–758. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bessard A, Frémin C, Ezan F, et al:
RNAi-mediated ERK2 knockdown inhibits growth of tumor cells in
vitro and in vivo. Oncogene. 27:5315–5325. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Obajimi O and Melera P: Suppression of
ERK1/2 with siRNA restores drug sensitivity in DU145 cells selected
for resistance to AG2034 (abstract 77). Cancer Res. 70(Suppl
1)2010. View Article : Google Scholar
|
|
46
|
Smalley KS: A pivotal role for ERK in the
oncogenic behaviour of malignant melanoma? Int J Cancer.
104:527–532. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gao J, Zhao Y, Lv Y, et al: Mirk/Dyrk1B
mediates G0/G1 to S phase cell cycle progression and cell survival
involving MAPK/ERK signaling in human cancer cells. Cancer Cell
Int. 13:22013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Balmanno K and Cook SJ: Tumour cell
survival signalling by the ERK1/2 pathway. Cell Death Differ.
16:368–377. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lin YC, Wu MH, Wei TT, et al: Degradation
of epidermal growth factor receptor mediates dasatinib-induced
apoptosis in head and neck squamous cell carcinoma cells.
Neoplasia. 14:463–475. 2012.PubMed/NCBI
|
|
50
|
Ji WT, Chen HR, Lin CH, et al: Monocyte
chemotactic protein 1 (MCP-1) modulates pro-survival signaling to
promote progression of head and neck squamous cell carcinoma. PLoS
One. 9:e889522014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang L, Liu T, Nishioka M, et al:
Activation of ERK1/2 and cyclin D1 expression in oral tongue
squamous cell carcinomas: relationship between clinicopathological
appearances and cell proliferation. Oral Oncol. 42:625–631. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bancroft CC, Chen Z, Dong G, et al:
Coexpression of proangiogenic factors IL-8 and VEGF by human head
and neck squamous cell carcinoma involves coactivation by MEK-MAPK
and IKK-NF-kappaB signal pathways. Clin Cancer Res. 7:435–442.
2001.PubMed/NCBI
|
|
53
|
Duvvuri U, Shiwarski DJ, Xiao D, et al:
TMEM16A induces MAPK and contributes directly to tumorigenesis and
cancer progression. Cancer Res. 72:3270–3281. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Li B, Lu L, Zhong M, Tan XX, et al:
Terbinafine inhibits KSR1 and suppresses Raf-MEK-ERK signaling in
oral squamous cell carcinoma cells. Neoplasma. 60:406–412. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lavoie JN, L’Allemain G, Brunet A, et al:
Cyclin D1 expression is regulated positively by the p42/p44MAPK and
negatively by the p38/HOGMAPK pathway. J Biol Chem.
271:20608–20616. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhao Y, Lv M, Lin H, et al: Rho-associated
protein kinase isoforms stimulate proliferation of vascular smooth
muscle cells through ERK and induction of cyclin D1 and PCNA.
Biochem Biophys Res Commun. 432:488–493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Si H, Peng C, Li J, Wang X, et al:
RNAi-mediated knockdown of ERK1/2 inhibits cell proliferation and
invasion and increases chemosensitivity to cisplatin in human
osteosarcoma U2-OS cells in vitro. Int J Oncol.
40:1291–1297. 2012.PubMed/NCBI
|
|
58
|
Dumesic PA, Scholl FA, Barragan DI and
Khavari PA: Erk1/2 MAP kinases are required for epidermal G2/M
progression. J Cell Biol. 185:409–422. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Judd NP, Winkler AE, Murillo-Sauca O, et
al: ERK1/2 regulation of CD44 modulates oral cancer aggressiveness.
Cancer Res. 72:365–374. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Katada K, Tomonaga T, Satoh M, et al:
Plectin promotes migration and invasion of cancer cells and is a
novel prognostic marker for head and neck squamous cell carcinoma.
J Proteomics. 75:1803–1815. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zuo JH, Zhu W, Li MY, et al: Activation of
EGFR promotes squamous carcinoma SCC10A cell migration and invasion
via inducing EMT-like phenotype change and MMP-9-mediated
degradation of E-cadherin. J Cell Biochem. 112:2508–2517. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Li R, You S, Hu Z, et al: Inhibition of
STAT3 by niclosamide synergizes with erlotinib against head and
neck cancer. PLoS One. 8:e746702013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Wakahara R, Kunimoto H, Tanino K, et al:
Phospho-Ser727 of STAT3 regulates STAT3 activity by enhancing
dephosphorylation of phospho-Tyr705 largely through TC45. Genes
Cells. 17:132–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Hazan-Halevy I, Harris D, Liu Z, Liu J, et
al: STAT3 is constitutively phosphorylated on serine 727 residues,
binds DNA, and activates transcription in CLL cells. Blood.
115:2852–2863. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sakaguchi M, Oka M, Iwasaki T, et al: Role
and regulation of STAT3 phosphorylation at Ser727 in melanocytes
and melanoma cells. J Invest Dermatol. 132:1877–1885. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Miyakoshi M, Yamamoto M, Tanaka H and
Ogawa K: Serine 727 phosphorylation of STAT3: an early change in
mouse hepatocarcinogenesis induced by neonatal treatment with
diethylnitrosamine. Mol Carcinog. 53:67–76. 2014. View Article : Google Scholar
|
|
67
|
Wierenga AT, Vogelzang I, Eggen BJ and
Vellenga E: Erythropoietin-induced serine 727 phosphorylation of
STAT3 in erythroid cells is mediated by a MEK-, ERK-, and
MSK1-dependent pathway. Exp Hematol. 31:398–405. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Nelson EA, Walker SR, Kepich A, et al:
Nifuroxazide inhibits survival of multiple myeloma cells by
directly inhibiting STAT3. Blood. 112:5095–5102. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Sumimoto H, Imabayashi F, Iwata T and
Kawakami Y: The BRAF-MAPK signaling pathway is essential for
cancer-immune evasion in human melanoma cells. J Exp Med.
203:1651–1656. 2006. View Article : Google Scholar : PubMed/NCBI
|
